FindTrial
Sign In

Curcumin and amla containing ointment for contact dermatitis : a randomised control trial of chemotherapy PICC patient

â??A randomized controlled trial to assess the effect of curcumin and amla containing ointment on PICC related contact dermatitis in patients receiving chemotherapy at TMH Mumbaiâ??

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053380
Enrollment
170
Registered
2023-06-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L231- Allergic contact dermatitis due toadhesives Health Condition 2: L235- Allergic contact dermatitis due toother chemical products Health Condition 3: L239- Allergic contact dermatitis, unspecified cause

Interventions

None listed

Sponsors

Pharmanza Herbal Pvt Ltd,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-65 years of both the sex. 2. Patient with PICC line for chemotherapy having 3. Contact dermatitis of any grade 1- 4. 4. Patient willing to participate and give consent.

Exclusion criteria

Exclusion criteria: 1. Patient with a known history of eczema and allergy. 2. Patient on antiallergic treatment/ taking medications. 3. The patients with known liver/Renal metastasis and impairment

Design outcomes

Primary

MeasureTime frame
To assess time of resolution of contact dermatitis by application of amla and curcumin containing cream. Timepoint: For Contact dermatitis of grade 1-2 the assessment will be done on On day 4th, 8th, 12th, 16th, 20th, 24th and 28th (2nd to 7th intervention)—

Secondary

MeasureTime frame
1. To find incidence of early onset contact dermatitis. 2. To assess the safety of curcumin and amla containing ointmentTimepoint: on 27 days in 1-2 grade and 29 days in 3-4 grade of contact dermatitis.—

Countries

India

Contacts

Public ContactDakshata Talekar

Tata Memorial Hospital

dsouza.angaikwad@gmail.com9833784429

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026